Tags : Discover

Biotech

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover

Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies […]Read More

Biotech

SMA Foundation Collaborates with PTC to Discover and Develop Regenerative

Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases The focus of the agreement is advance scientific research in SMA and other neuromuscular disorders to develop new treatments The availability of several disease-modifying therapies has made regenerative interventions the […]Read More

Biotech

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies

Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration The collaboration will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel Ab-based […]Read More

Biotech

Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific

Shots: Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, […]Read More

Pharma

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and

Shots: Frontier to receive$55M up front and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products. The company might get ~45M within the first 12mos. of collaboration Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas […]Read More

Pharma

Eisai Sign a Research Agreement with Wren Therapeutics to Discover

Shots: The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience in drug discovery for neurodegenerative disorders, to accelerate the development […]Read More